# Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

> **NCT07168876** · — · RECRUITING · sponsor: **Epiliquid Holding, Inc** · enrollment: 3200 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07168876
- **Lead sponsor:** Epiliquid Holding, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-04
- **Primary completion:** 2025-12
- **Final completion:** 2028-12
- **Target enrollment:** 3200 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168876, "Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07168876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*